Literature DB >> 20606012

Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor.

Yu Zheng1, Maoyu Peng, Zebin Wang, John M Asara, Angela L Tyner.   

Abstract

Protein tyrosine kinase 6 (PTK6) is a nonmyristoylated Src-related intracellular tyrosine kinase. Although not expressed in the normal mammary gland, PTK6 is expressed in a majority of human breast tumors examined, and it has been linked to ErbB receptor signaling and AKT activation. Here we demonstrate that AKT is a direct substrate of PTK6 and that AKT tyrosine residues 315 and 326 are phosphorylated by PTK6. Association of PTK6 with AKT occurs through the SH3 domain of PTK6 and is enhanced through SH2 domain-mediated interactions following tyrosine phosphorylation of AKT. Using Src, Yes, and Fyn null mouse embryonic fibroblasts (SYF cells), we show that PTK6 phosphorylates AKT in a Src family kinase-independent manner. Introduction of PTK6 into SYF cells sensitized these cells to physiological levels of epidermal growth factor (EGF) and increased AKT activation. Stable introduction of active PTK6 into SYF cells also resulted in increased proliferation. Knockdown of PTK6 in the BPH-1 human prostate epithelial cell line led to decreased AKT activation in response to EGF. Our data indicate that in addition to promoting growth factor receptor-mediated activation of AKT, PTK6 can directly activate AKT to promote oncogenic signaling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20606012      PMCID: PMC2937549          DOI: 10.1128/MCB.00024-10

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  55 in total

1.  Regulation of Akt/PKB activation by tyrosine phosphorylation.

Authors:  R Chen; O Kim; J Yang; K Sato; K M Eisenmann; J McCarthy; H Chen; Y Qiu
Journal:  J Biol Chem       Date:  2001-07-09       Impact factor: 5.157

2.  Identification of tyrosine kinases overexpressed in head and neck cancer.

Authors:  Ho-Sheng Lin; Gerald J Berry; Willard E Fee; David J Terris; Zijie Sun
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2004-03

3.  4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway.

Authors:  A C Gingras; S G Kennedy; M A O'Leary; N Sonenberg; N Hay
Journal:  Genes Dev       Date:  1998-02-15       Impact factor: 11.361

4.  Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RNA binding ability.

Authors:  J J Derry; S Richard; H Valderrama Carvajal; X Ye; V Vasioukhin; A W Cochrane; T Chen; A L Tyner
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

5.  Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation.

Authors:  Tianyun Jiang; Yun Qiu
Journal:  J Biol Chem       Date:  2003-02-24       Impact factor: 5.157

6.  Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition.

Authors:  Haoqun Qiu; W Todd Miller
Journal:  J Biol Chem       Date:  2002-07-16       Impact factor: 5.157

7.  Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells.

Authors:  Jason J Derry; Gail S Prins; Vera Ray; Angela L Tyner
Journal:  Oncogene       Date:  2003-07-03       Impact factor: 9.867

8.  Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase.

Authors:  Nelly Marmy Conus; Katherine M Hannan; Briony E Cristiano; Brian A Hemmings; Richard B Pearson
Journal:  J Biol Chem       Date:  2002-07-30       Impact factor: 5.157

Review 9.  Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases.

Authors:  Michael S Serfas; Angela L Tyner
Journal:  Oncol Res       Date:  2003       Impact factor: 5.574

10.  Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation.

Authors:  Amanda J Harvey; Mark R Crompton
Journal:  Oncogene       Date:  2003-08-07       Impact factor: 9.867

View more
  33 in total

Review 1.  Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.

Authors:  Alessia Locatelli; Kristopher A Lofgren; Andrea R Daniel; Nancy E Castro; Carol A Lange
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

Review 2.  PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics.

Authors:  Kiran Mahajan; Nupam P Mahajan
Journal:  J Cell Physiol       Date:  2012-09       Impact factor: 6.384

3.  AKT goes cycling.

Authors:  Kiran N Mahajan; Nupam P Mahajan
Journal:  Cancer Control       Date:  2014-07       Impact factor: 3.302

4.  Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition.

Authors:  Tiffany Tsui; W Todd Miller
Journal:  Biochemistry       Date:  2015-05-13       Impact factor: 3.162

5.  Vemurafenib Inhibits Active PTK6 in PTEN-null Prostate Tumor Cells.

Authors:  Darren J Wozniak; Ben Hitchinson; Milica B Gilic; Wenjun Bie; Vadim Gaponenko; Angela L Tyner
Journal:  Mol Cancer Ther       Date:  2019-03-29       Impact factor: 6.261

6.  Disruption of the mouse protein tyrosine kinase 6 gene prevents STAT3 activation and confers resistance to azoxymethane.

Authors:  Jessica Gierut; Yu Zheng; Wenjun Bie; Robert E Carroll; Susan Ball-Kell; Andrea Haegebarth; Angela L Tyner
Journal:  Gastroenterology       Date:  2011-07-08       Impact factor: 22.682

7.  Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer.

Authors:  Priya S Mathur; Jessica J Gierut; Grace Guzman; Hui Xie; Rosa M Xicola; Xavier Llor; Michael I Chastkofsky; Ansu O Perekatt; Angela L Tyner
Journal:  Mol Cancer Res       Date:  2016-03-16       Impact factor: 5.852

Review 8.  Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.

Authors:  Michelle J Lee; Nan Jin; Jennifer R Grandis; Daniel E Johnson
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2020-02-19       Impact factor: 4.739

Review 9.  Targeting protein tyrosine kinase 6 in cancer.

Authors:  Milica B Gilic; Angela L Tyner
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-09-18       Impact factor: 10.680

10.  The alternative splice variant of protein tyrosine kinase 6 negatively regulates growth and enhances PTK6-mediated inhibition of β-catenin.

Authors:  Patrick M Brauer; Yu Zheng; Mark D Evans; Carmen Dominguez-Brauer; Donna M Peehl; Angela L Tyner
Journal:  PLoS One       Date:  2011-03-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.